Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants

被引:33
|
作者
Zhao, XD
Chen, FP
Megaw, AG
Sullender, WM
机构
[1] Univ Alabama, Dept Pediat, Birmingham, AL 35233 USA
[2] Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA
来源
JOURNAL OF INFECTIOUS DISEASES | 2004年 / 190卷 / 11期
关键词
D O I
10.1086/425515
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Palivizumab (PZ) is the only monoclonal antibody in use against a human infectious disease. PZ is given as prophylaxis against infection with respiratory syncytial virus (RSV). An RSV escape mutant, MP4, has been shown to resist PZ prophylaxis in cotton rats. Methods. To further define the potential of RSV to resist prophylaxis, additional PZ-resistant viruses were selected in cell culture and were tested for susceptibility to PZ in cotton rats. Results. Mutant MS412 had an A-->C mutation at nucleotide position 827 in the F gene, resulting in an amino acid change from Lys to Gln at position 272. Mutant F212 had an A-->T mutation at position 816, leading to an amino acid change from Asn to Ile at position 268. In vitro, F212 had impaired growth kinetics. In cell culture, F212 was partially and MS412 was completely resistant to PZ neutralization. A single prophylactic dose of 15 mg/kg PZ protected cotton rats from infection with F212 but not with MS412. Conclusion. Both in vitro and in vivo, individual RSV PZ escape mutants varied in their susceptibility to PZ. Mutations associated with resistance to PZ did not always result in failure of PZ prophylaxis.
引用
收藏
页码:1941 / 1946
页数:6
相关论文
共 50 条
  • [1] Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats
    Zhao, XD
    Chen, FP
    Sullender, WM
    [J]. VIROLOGY, 2004, 318 (02) : 608 - 612
  • [2] Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants
    DeVincenzo, JP
    Hall, CB
    Kimberlin, DW
    Sánchez, PJ
    Rodriguez, WJ
    Jantausch, BA
    Corey, L
    Kahn, JS
    Englund, JA
    Suzich, JA
    Palmer-Hill, FJ
    Branco, L
    Johnson, S
    Patel, NK
    Piazza, FM
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (05): : 975 - 978
  • [3] PALIVIZUMAB FOR RESPIRATORY SYNCYTIAL VIRUS DISEASE
    Carrera, G.
    D'alterio, R.
    Leone, G.
    Zambetti, C.
    [J]. MINERVA PEDIATRICA, 2013, 65 (05) : 505 - 512
  • [4] Palivizumab and emerging therapies for respiratory syncytial virus
    Hoopes, John Michael
    Makari, Doris
    Groothuis, Jessie
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (05) : 547 - 548
  • [5] Palivizumab for the prevention of respiratory syncytial virus infection
    Rogovik, Alexander L.
    Carleton, Bruce
    Solimano, Alfonso
    Goldman, Ran
    [J]. CANADIAN FAMILY PHYSICIAN, 2010, 56 (08) : 769 - 772
  • [6] Palivizumab in the prevention of respiratory syncytial virus disease
    Krilov, LR
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (07) : 763 - 769
  • [7] Is immunoprophylaxis with palivizumab justified for respiratory syncytial virus?
    Paul, Siba P.
    Ball, Georgina M.
    [J]. BRITISH JOURNAL OF HOSPITAL MEDICINE, 2017, 78 (08) : 476 - 476
  • [8] MECHANISMS OF IMMUNITY TO RESPIRATORY SYNCYTIAL VIRUS IN COTTON RATS
    PRINCE, GA
    HORSWOOD, RL
    CAMARGO, E
    KOENIG, D
    CHANOCK, RM
    [J]. INFECTION AND IMMUNITY, 1983, 42 (01) : 81 - 87
  • [9] Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab
    Chan, Parco
    Li, Abby
    Paes, Bosco
    Abraha, Haben
    Mitchell, Ian
    Lanctot, Krista L.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2015, 34 (12) : E290 - E297
  • [10] Treatment of respiratory syncytial virus with palivizumab: a systematic review
    Hu, Jia
    Robinson, Joan L.
    [J]. WORLD JOURNAL OF PEDIATRICS, 2010, 6 (04) : 296 - 300